Patents by Inventor Akito Shibuya
Akito Shibuya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240066047Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.Type: ApplicationFiled: May 1, 2023Publication date: February 29, 2024Inventors: MASATO YOSHIKAWA, MORIHISA SAITOH, TAISUKE KATO, YAYOI NAKAYAMA, TOMOHIRO SEKI, YASUO NAKAGAWA, YUSUKE TOMINARI, MASAKI SETO, YUSUKE SASAKI, MASANORI OKANIWA, TSUNEO ODA, AKITO SHIBUYA, KOSUKE HIDAKA, ZENYU SHIOKAWA, SHUMPEI MURATA, ATSUTOSHI OKABE, YOSHIHISA NAKADA, MICHIYO MOCHIZUKI, BRIAN SCOTT FREEZE, TAISUKE TAWARAISHI, YASUFUMI WADA, PAUL D. GREENSPAN
-
Patent number: 11795172Abstract: The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 24, 2021Date of Patent: October 24, 2023Assignee: Cardurion Pharmaceuticals, Inc.Inventors: Nobuyuki Matsunaga, Junya Shirai, Tomohiro Okawa, Yasufumi Miyamoto, Zenyu Shiokawa, Takashi Nakahata, Akito Shibuya, Akira Kawada, Malcolm MacCoss
-
Patent number: 11666594Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.Type: GrantFiled: October 7, 2020Date of Patent: June 6, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Masato Yoshikawa, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
-
Publication number: 20220112184Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: September 24, 2021Publication date: April 14, 2022Inventors: Nobuyuki MATSUNAGA, Yasufumi MIYAMOTO, Junya SHIRAI, Takashi NAKAHATA, Zenyu SHIOKAWA, Tomohiro OKAWA, Akito SHIBUYA, Malcolm MACCOSS
-
Publication number: 20220098207Abstract: The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 24, 2021Publication date: March 31, 2022Inventors: Nobuyuki MATSUNAGA, Junya SHIRAI, Tomohiro OKAWA, Yasufumi MIYAMOTO, Zenyu SHIOKAWA, Takashi NAKAHATA, Akito SHIBUYA, Akira KAWADA, Malcolm MACCOSS
-
Patent number: 11197858Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: January 27, 2020Date of Patent: December 14, 2021Assignee: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
-
Patent number: 11186565Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.Type: GrantFiled: March 29, 2018Date of Patent: November 30, 2021Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Seiji Miwatashi, Yasufumi Miyamoto, Koji Watanabe, Yayoi Nakayama, Yuko Hitomi, Jumpei Aida, Nobuyuki Takakura, Hideki Furukawa, Naoyoshi Noguchi, Yasuhiro Hirata, Kazuaki Takami, Norihito Tokunaga, Tomohiro Okawa, Akito Shibuya, Shizuo Kasai, Toshitake Kobayashi, Tsuyoshi Maekawa
-
Patent number: 11130752Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: September 24, 2019Date of Patent: September 28, 2021Assignee: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki Matsunaga, Yasufumi Miyamoto, Junya Shirai, Takashi Nakahata, Zenyu Shiokawa, Tomohiro Okawa, Akito Shibuya, Malcolm MacCoss
-
Publication number: 20210137962Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.Type: ApplicationFiled: November 9, 2018Publication date: May 13, 2021Inventors: Masato Yoshikawa, Morihisa Saitoh, Taisuke Kato, Yayoi Yoshitomi, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Yoshihisa Nakada, Michiyo Mochizuki
-
Patent number: 10980825Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.Type: GrantFiled: November 9, 2018Date of Patent: April 20, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Masato Yoshikawa, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Yoshihisa Nakada, Michiyo Mochizuki
-
Publication number: 20210106607Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.Type: ApplicationFiled: October 7, 2020Publication date: April 15, 2021Inventors: MASATO YOSHIKAWA, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
-
Publication number: 20200230137Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: January 27, 2020Publication date: July 23, 2020Applicant: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA
-
Publication number: 20200095240Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: September 24, 2019Publication date: March 26, 2020Inventors: Nobuyuki MATSUNAGA, Yasufumi MIYAMOTO, Junya SHIRAI, Takashi NAKAHATA, Zenyu SHIOKAWA, Tomohiro OKAWA, Akito SHIBUYA, Malcolm MacCoss
-
Patent number: 10543212Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: March 23, 2018Date of Patent: January 28, 2020Assignee: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
-
Publication number: 20190192549Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.Type: ApplicationFiled: November 9, 2018Publication date: June 27, 2019Inventors: MASATO YOSHIKAWA, Morihisa Saitoh, Taisuke Kato, Yayoi Yoshitomi, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
-
Publication number: 20180280389Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: March 23, 2018Publication date: October 4, 2018Applicant: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA
-
Patent number: 9890145Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: April 25, 2016Date of Patent: February 13, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Masato Yoshida, Kazuaki Takami, Yusuke Tominari, Zenyu Shiokawa, Akito Shibuya, Yusuke Sasaki, Tony Gibson, Terufumi Takagi
-
Patent number: 9776962Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.Type: GrantFiled: August 8, 2014Date of Patent: October 3, 2017Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Jumpei Aida, Yayoi Yoshitomi, Yuko Hitomi, Naoyoshi Noguchi, Yasuhiro Hirata, Hideki Furukawa, Akito Shibuya, Koji Watanabe, Yasufumi Miyamoto, Tomohiro Okawa, Nobuyuki Takakura, Seiji Miwatashi
-
Publication number: 20160311811Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: April 25, 2016Publication date: October 27, 2016Applicant: Takeda Pharmaceutical Company LimitedInventors: Masato YOSHIDA, Kazuaki TAKAMI, Yusuke TOMINARI, Zenyu SHIOKAWA, Akito SHIBUYA, Yusuke SASAKI, Tony GIBSON, Terufumi TAKAGI
-
Patent number: 9382188Abstract: Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.Type: GrantFiled: February 12, 2013Date of Patent: July 5, 2016Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Seiji Miwatashi, Hideo Suzuki, Tomohiro Okawa, Yasufumi Miyamoto, Takeshi Yamasaki, Yuko Hitomi, Yasuhiro Hirata, Akito Shibuya